The Centers for Medicare & Medicaid Services has issued a permanent billing and reimbursement J-code, J9183, for the ...

Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months ...

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data GuidancePhase 1b/2 NMIBC Trial on Track: ...

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its ...

I was diagnosed with a large fatty tumor on my left thigh. It’s very ugly. What can I do to get rid of it? — V.O.P.

Nadofaragene firadenovec-vncg is the only FDA-approved nonreplicating intravesical gene therapy for high-risk ...

En bloc resection of bladder tumor has recently emerged as an alternative to TURBT aiming to improve surgical quality and pathological assessment.

Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products ...

A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

Detailed price information for Relmada Therapeutics Inc (RLMD-Q) from The Globe and Mail including charting and trades.

—A recent meta-analysis of 35 studies showed that TURP was associated with lower odds of early and persistent LUTS compared with ablation and enucleation. After surgery for benign prostatic ...

Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer operations, finds a new clinical trial led by researchers at UCL, UCLH and the ...